Furthermore, although the combination of PD-1/PD-L1 blockade with complementary checkpoint inhibitors has achieved some success for some malignant tumors in the preclinical and clinical trials, the impact of PD-1 on immune cells in addition to T cells and the synergistic role of PD-1 with other immune modulators remain mostly unknown (17). This evidence concerns the gene CD274 and cancer.